Sanara MedTech (SMTI) and Its Competitors Head-To-Head Review

Sanara MedTech (NASDAQ:SMTI) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare Sanara MedTech to related companies based on the strength of its valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.

Institutional and Insider Ownership

8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 42.0% of Sanara MedTech shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Sanara MedTech and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Sanara MedTech	$103.12 million	-$37.56 million	-9.06
Sanara MedTech Competitors	$1.87 billion	$137.20 million	5.88

Sanara MedTech’s rivals have higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Sanara MedTech and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	29.72%	2.84%
Sanara MedTech Competitors	-303.57%	-175.14%	-22.20%

Risk and Volatility

Sanara MedTech has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Sanara MedTech’s rivals have a beta of 2.57, suggesting that their average stock price is 157% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Sanara MedTech and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1	4	0	0	1.80
Sanara MedTech Competitors	4295	10585	18372	832	2.46

Sanara MedTech presently has a consensus target price of $35.00, indicating a potential upside of 7.56%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.55%. Given Sanara MedTech’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Sanara MedTech has less favorable growth aspects than its rivals.

Summary

Sanara MedTech rivals beat Sanara MedTech on 8 of the 13 factors compared.

About Sanara MedTech

Sanara MedTech, Inc. develops, markets and distributes medical products for wound care, surgical tissue repair and related applications. Its offerings are intended for use by healthcare professionals treating acute and chronic wounds and supporting tissue healing. The company’s portfolio includes CellerateRX® collagen-based products and BIAKŌS® antimicrobial products, along with other solutions for wound and surgical care. Sanara sells its products to healthcare providers and through distribution channels.